Management of Acute Coronary Syndrome / NSTEMI

Size: px
Start display at page:

Download "Management of Acute Coronary Syndrome / NSTEMI"

Transcription

1 CLINICAL GUIDELINE Management of Acute Coronary Syndrome / NSTEMI For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: All clinical areas Medical and Nursing Staff Possible Cardiac Chest Pain/ACS Dr Ajit Agarwal APPROVED Purpose of the Guideline Acute coronary syndrome (ACS) is a general term encompassing the conditions of unstable angina (UA) and myocardial infarction (MI). This guideline covers the initial management of patients suffering non-st segment myocardial infarction (NSTEMI) and those with suspected ACS. Patients with an ST-segment elevation MI (STEMI) should be treated in accordance with the Acute Myocardial Infarction Pathway (STEMI). This guideline has been produced to promote consistent care of patients experiencing ACS / NSTEMI across the trust. It may be of particular benefit to staff that do not care for these patients routinely. Whilst based on scientific evidence or professional consensus these guidelines are not intended to replace clinical judgment. Contents. Page Treatment pathway for the management of patients with suspected ACS 2 Pathway for anti-platelet therapy in patients prescribed warfarin 3 Clinical management specific elements of treatment / management o Presentation with Suspected ACS 4 o ECG 5 o Blood Tests 5 o When acute coronary syndrome is confirmed 5 Appendix 1 6 References 7 Source: Issue date: 5th March 2012 Page 1 of 7

2 Pathway for the management of acute coronary syndromes (ACS) Suspected cardiac chest pain 12 lead ECG IMMEDIATELY Changes suggestive of NEW STEMI or LBBB Consider Urgent Referral for PPCI at Papworth NEW Changes indicative of NSTEMI / ACS GTN S/L, O 2 100% - Refer to O 2 guideline if saturations <94%, Aspirin & Clopidogrel 300mg PO stat unless given pre-hospital, Fondaparinux 2.5mg S/C or THROMBOLYSIS (CCU or ED) see PPCI pathway on Pink Book Secure IV access and Px morphine / diamorphine IV and cyclizine / metocolpramide PRN Trop. T ve Stop fondaparinux and clopidogrel Non-cardiac chest pain: Review remaining medications based upon cardiovascular risk factors and consider discharge home if stable Cardiac chest pain: Refer for ETT either as as O/P or I/P or MPI as O/P Review medication according to clinical picture Where appropriate Px: Aspirin 75mg PO OM Clopidogrel 75mg PO OM Fondaparinux 2.5mg S/C OD* Simvastatin 40mg PO Nocté Bisoprolol low dose and titrate according to response Ramipril low dose and titrate according to response Troponin T level 12 hours after onset of symptoms Trop. T +ve Continue fondaparinux for up to 8/7 or hospital discharge (which ever is the sooner) Continue clopidogrel for 1 year Refer for Cardiology review prior to hospital discharge Home Day 5 1-3% (low risk) & pain free transfer to G3 repeat ECG Complete Grace score if Troponin T level available >3% (high risk) admit to CCU Ischaemic ECG Or On-going pain and High risk patient Haemodynamically compromised Previous MI, PTCA, CABG LV dysfunction > 70 yrs + other risks Consider tirofiban infusion and whiteboard urgent I/P coronary angiogram at Papworth Trop. T level 12 hours after onset of pain Ongoing or recurrent chest pain: give analgesia / antiemetics as required and start GTN IV infusion transfer to CCU for continuous ECG monitoring Trop. T -ve Refer for ETT either as O/P or I/P or MPI as O/P at physician s discretion Review medication according to clinical picture Trop. T +ve Angiogram: I/P if clinically indicated or O/P - Home day 5 * For patients with renal impairment (SeCr >265µmol/L or EGFR <20mL/min) OMIT FONDAPARINUX and prescribe ENOXAPARIN 1mg/kg S/C OD Troponin T on admission if history of chest pain for 12 hrs at the time of arrival. Source: Issue date: 5th March 2012 Page 2 of 7

3 Pathway for anti-platelet therapy in patients taking warfarin prior to admission Warfarin used for AF / VTE: STAT doses of each: Aspirin 300mg PO Clopidogrel 300mg PO Fondaparinux 2.5mg SC Withhold warfarin Suspected ACS Trop. T 12 hours after onset of pain If > 30ng/L and diagnosis of ACS confirmed Warfarin used for valve prosthesis: STAT doses of each: Aspirin 300mg PO Clopidogrel 300mg PO Continue warfarin If INR 2 the give additional fondaparinux 2.5mg SC OD until INR therapeutic Prescribe the following regularly: Aspirin 75mg PO OD Clopidogrel 75mg PO OD Fondaparinux 2.5mg SC OD for up to 8/7 or hospital discharge Prescribe the following regularly: Continue warfarin Aspirin 75mg PO OD Clopidogrel 75mg PO OD Fondaparinux 2.5mg SC OD for up to 8/7 or hospital discharge 1-2 days prior to cessation of fondaparinux test INR and re-load / re-prescribe warfarin maintenance dose accordingly On discharge: Aspirin 75mg PO OD Clopidogrel 75mg PO OD for 1-6 months depending upon bleeding risk Warfarin continue On discharge: Aspirin 75mg PO OD Clopidogrel 75mg PO OD for 1-6 months depending upon bleeding risk Warfarin - continue When prescribing warfarin discharge doses and INR test dates please consider any new drug interactions which affect the INR Clinical judgment should still be used when considering use of antiplatelet agents patients with confirmed ACS balance treatment of ACS vs. risk of bleeding with combination therapy For patients with renal impairment (SeCr >265µmol/L or EGFR <20mL/min) OMIT FONDAPARINUX and prescribe ENOXAPARIN 1mg/kg S/C OD Source: Issue date: 5th March 2012 Page 3 of 7

4 1. Presentation with Suspected ACS 1.1 Patients with suspected cardiac pain, continual or recurrent, and unresolved after 20 minutes should be taken to an acute hospital. All patients with suspected ACS should receive: - GTN - S/L or buccal & prescribed PRN - Oxygen 100% (if O 2 saturations <94% see O 2 guideline) - Aspirin 300mg PO STAT - Clopidogrel 300mg PO STAT (unless administered prior to admission) - Fondaparinux 2.5 mg SC (for patients with renal impairment (SeCr >265µmol/L of EGFR <20mL/min)) OMIT fondaparinux and prescribe enoxaparin 1mg/Kg For further prescribing advise regarding the use of fondaparinux please see separate fondaparinux guideline - IV access - Diamorphine 2.5-5mg / Morphine 5-10mg IV PRN for pain relief. - Beta-blocker introduce cautiously if large MI, titrate to response and withhold if acute heart failure - Statin therapy prescribe simvastatin 40mg PO nocte as first line and adjust dose depending upon drug interactions and monitor liver function - ACE inhibitor prescribe ramipril as first line at night and titrate dose to maximum tolerated licensed dose (target ramipril 10mg OD). Monitor renal function closely. - Cardiac rhythm monitoring - Standard 12 lead ECG - Baseline vital signs - BP, Pulse, SaO 2, Resp rate and Temp Clinical judgment should still be used when considering use of antiplatelets in suspected/confirmed ACS balance risk of ACS with risk of bleeding when prescribing. Standard prescribing recommendations for drugs mentioned above apply. 1.2 All patients should be referred to, and assessed by a cardiologist within 24 hours of presentation if possible (except during the weekend when referrals will have to be made as soon as possible on Monday morning). 1.3 Risk assessment to guide appropriate treatment and placement on Cardiac Care Unit (CCU) or cardiac ward (G3) calculate Global Registry of Acute Cardiac Events (GRACE) score at and see appendix 1 for respective risk. The link above can be accessed directly through the WSH intranet home page via Patient Info, Cardiology, and Grace Calculator. 1.4 Low risk suspected ACS patients should be admitted to G3. Moderate to high risk patients should be admitted to CCU. 1.5 PLEASE NOTE: Cardiac arrest and subsequent neuro-protective strategies (e.g. cooling of core body temperature conducted in Critical Care) should not preclude application of this guideline where appropriate. Source: Issue date: 5th March 2012 Page 4 of 7

5 2. ECG 2.1 All patients with suspected ACS should have a 12 lead ECG performed immediately on admission. 2.2 Patients with persistent ST elevation or new left bundle branch block - refer to Pink Book for STEMI / PPCI guidelines and pathway. 2.3 Patients without ST elevation - repeat ECG at 15 minute intervals if pain is ongoing or recurrent. Only discontinue when the ECG is unchanging. Utilise ST segment monitoring if available. 2.4 All patients with abnormal ECG (ST depression - transient ST elevation) should have blood samples taken for Troponin T to aid diagnosis. 3. Blood tests 3.1 Blood sample for cardiac Troponin T should be taken 12 hours after cardiac event / onset of symptoms if timing is accurate. 3.2 Where symptoms were experienced greater than 12 hours ago send blood sample for cardiac Troponin T immediately. 3.3 As a guide the following has been agreed to aid diagnosis of NSTEMI: Detection of a rise (or fall if late presentation) of troponin with at least one result above 29ng/l together with evidence of myocardial ischaemia as recognised by at least one of the following: - Symptoms of ischaemia - ECG changes of new ischemia (ESC 2007) Those patients with high suspicion of cardiac pain and with borderline rises in troponin (14-30ng/l) should have a further troponin 6hrs or more later, to clarify if the troponin level is still rising, and hence confirming the diagnosis of NSTEMI. Clinicians must be aware that troponin levels can rise in non-ischaemic related conditions e.g. sepsis, tachyarrhythmia, severe renal impairment and pulmonary embolus, so caution should be taken when making diagnoses on the basis of a biomarker alone. 3.3 Blood should also be taken for: FBC, U&E, Glucose, lipids & LFT 4 When acute coronary syndrome is confirmed. 4.1 The patient should be admitted to the Emergency Admissions Unit, G3 or CCU and have continuous ECG monitoring. 4.2 The patient should receive aspirin75mg PO OD (to continue lifelong if tolerated) and clopidogrel 75 mg PO OD (to continue for 12 months), Fondaparinux 2.5mg S/C OD for up to 8 days or until hospital discharge (which ever is the sooner), beta-blockers (bisoprolol first line), ACE inhibitor (ramipril first line)and GTN S/L prn. 4.3 For patients with renal impairment (SeCr >265µmol/L or EGFR <20mL/min) omit fondaparinux and prescribe enoxaparin 1mg/kg S/C OD 4.4 For patients who are on warfarin see flowchart above. 4.5 Tirofiban (Glycoprotein IIb/IIIa inhibitor - antiplatelet) and early percutaneous coronary intervention (PCI) should be considered for those with medium / high risk features who experience further / persistent ECG changes and ongoing chest pain(see flowchart) 4.6 Assess individual risk of future adverse cardiovascular events using an established risk scoring system that predicts 6-month mortality - GRACE. Source: Issue date: 5th March 2012 Page 5 of 7

6 Appendix 1 Non STE-ACS: In-hospital Mortality Risk Category (tertiles) GRACE Risk Score Probability of Death In-hospital (%) Low <1 Intermediate High >3 Non STE-ACS: 6 Month Post-discharge Mortality Risk Category (Tertiles) GRACE Risk Score Probability of Death Post-discharge to 6 Months (%) Low 1-88 <3 Intermediate High >8 Source: Issue date: 5th March 2012 Page 6 of 7

7 References Clinical guidelines for the management of suspected ACS/NSTEMI from Peterborough and Stamford Hospital.(2009) Author: Karen Wilkinson British Cardiac Society Guidelines and Medical Practice Committee, and Royal College of Physicians Clinical Effectiveness and Evaluation Unit. (2001) Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. Heart; 85:p National Institute for Clinical Excellence (July 2004) Clopidogrel in the treatment of non -ST-segment -elevation acute coronary syndrome. Department of Health (2000). National Service Framework. Coronary Heart Disease. Heart attacks & other acute coronary syndromes: Chapter 3:12:p5 The European Society of Cardiology (2007) Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. European Heart Journal (2007)28, The TIMI risk score for Unstable Angina/Non-ST Elevation MI (2000) Antman et al JAMA vol 284 no.7, European Society of Cardiology (2007) The universal definition of myocardial infarction.eur heart journal;28: Granger CB, Goldberg RJ, Dabbous OH et al. for the Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163: National Institute for Clinical Excellence (June 2010) Unstable angina and NSTEMI National Institute for Clinical Excellence (June 2010) Chest Pain of Acute Onset Author(s): Approved by: Issue no: Dr Ajit Agarwal AKA Source: Issue date: 5th March 2012 Page 7 of 7

URN: Family name: Given name(s): Address:

URN: Family name: Given name(s): Address: State of Queensland (Queensland Health) 2015 Licensed under: http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en Contact: Clinical_Pathways_Program@health.qld.gov.au Facility:... Clinical pathways

More information

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital

More information

Redefining the NSTEACS pathway in London

Redefining the NSTEACS pathway in London Redefining the NSTEACS pathway in London Sotiris Antoniou Consultant Pharmacist, Cardiovascular Medicine, Barts and The London NHS Trust and Project Lead, North East London Cardiovascular and Stroke Network

More information

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF

More information

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

Rivaroxaban for acute coronary syndromes

Rivaroxaban for acute coronary syndromes Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

ACUTE CORONARY SYNDROME (ACS)

ACUTE CORONARY SYNDROME (ACS) Date of admission. Time. Consultant ACUTE CORONARY SYNDROME (ACS) CARE PATHWAY Includes: All patients with cardiac sounding chest pain to be included in this pathway Excludes: Patients NOT managed as ACS

More information

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics Yen Tibayan, M.D. Division of Cardiovascular Medicine Case Presentation 69 y.o. woman calls 911 with the complaint of

More information

S Hutton, A Inglis, C McKiernan, S Hearns, P Campbell, M Lindsay

S Hutton, A Inglis, C McKiernan, S Hearns, P Campbell, M Lindsay Emergency Medical Retrieval Service (EMRS) www.emrs.scot.nhs.uk Standard Operating Procedure Public Distribution Title Acute Coronary Syndrome Version 4 Related Documents Author Alan Exton Reviewer S Hutton,

More information

EMR Tutorial Acute Coronary Syndrome

EMR Tutorial Acute Coronary Syndrome EMR Tutorial Acute Coronary Syndrome How to find the Acute Coronary Syndrome AAA Home Page 1 of 26 Master Tool Bar Icon When the Template button is clicked you will be presented with the preference list.

More information

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:

More information

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO REFERRAL HOSPITAL The Importance of Door In Door Out Time DIDO Time to Treatment is critical for STEMI patients For patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary

More information

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic

More information

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris Pros and cons of registers Prospective randomised trials constitute the cornerstone of "evidence-based" medicine, and they therefore

More information

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Name of the Procedure: Coronary Balloon Angioplasty 2. Select the Indication from the drop down of various indications

More information

Acute Coronary Syndrome

Acute Coronary Syndrome Acute Coronary Syndrome Quality Measures Length of Stay RCC Costs per Case Critical Event(s) Evaluation /Acute Phase ECG ASA on arrival (unless documented contraindication) Troponin STAT, repeat once in

More information

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia

More information

Efficient Evaluation of Chest Pain

Efficient Evaluation of Chest Pain Efficient Evaluation of Chest Pain Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL No Disclosures Outline Background Chest pain pathway Indications for stress test Stress test

More information

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen

More information

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Recommendations of the European Society of Cardiology Updated version December 2002 Task Force on management

More information

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize

More information

Surgery and Anti-Coagulation Agents

Surgery and Anti-Coagulation Agents CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Pre-admission clinics and surgical wards Personnel involved in surgical pre-assessment

More information

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015 Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet

More information

Addendum to Clinical Review for NDA 22-512

Addendum to Clinical Review for NDA 22-512 Addendum to Clinical Review for DA 22-512 Drug: Sponsor: Indication: Division: Reviewers: dabigatran (Pradaxa) Boehringer Ingelheim Prevention of stroke and systemic embolism in atrial fibrillation Division

More information

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.

More information

The new Heart Failure pathway

The new Heart Failure pathway The new Heart Failure pathway An integrated and seamless Strategy Dr Sunil Balani Definition of Heart Failure The inability of the heart to pump blood at a rate commensurate with the requirements of metabolising

More information

Ischemic Heart Disease: Angina Pectoris

Ischemic Heart Disease: Angina Pectoris Ischemic Heart Disease: Angina Pectoris Robert J. Straka, Pharm.D. FCCP Associate Professor University of Minnesota College of Pharmacy Minneapolis, Minnesota, USA strak001@umn.edu Learning Objectives

More information

Networking for optimal treatment of STEMI and NSTEMI. European Stent for life Project

Networking for optimal treatment of STEMI and NSTEMI. European Stent for life Project Networking for optimal treatment of STEMI and NSTEMI European Stent for life Project Dariusz Dudek on behalf of Department of Interventional Cardiology, Institute of Cardiology, Krakow, Poland The European

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

Guidelines for Use of Clopidogrel (Plavix )

Guidelines for Use of Clopidogrel (Plavix ) East Lancashire Medicines Management Board representing East Lancashire Hospitals NHS Trust, Lancashire Care Trust, Blackburn with Darwen PCT, East Lancs PCT Licensed Indications Guidelines for Use of

More information

New Oral Anticoagulants. How safe are they outside the trials?

New Oral Anticoagulants. How safe are they outside the trials? New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants

More information

SIGN 93 Acute coronary syndromes. A national clinical guideline Updated February 2013

SIGN 93 Acute coronary syndromes. A national clinical guideline Updated February 2013 Help us to improve SIGN guidelines - click here to complete our survey SIGN 93 Acute coronary syndromes A national clinical guideline Updated February 2013 Evidence KEY TO EVIDENCE STATEMENTS AND GRADES

More information

Description of problem Description of proposed amendment Justification for amendment ERG response

Description of problem Description of proposed amendment Justification for amendment ERG response KEY INACCURACIES Issue 1 Distinguishing between groups of STEMI patients Key issue throughout the report The ERG distinguishes between groups of STEMI patients defining four patient groups: STEMI without

More information

A PATIENT S GUIDE TO SECONDARY PREVENTION IN ACUTE CORONARY SYNDROME (ACS)

A PATIENT S GUIDE TO SECONDARY PREVENTION IN ACUTE CORONARY SYNDROME (ACS) A PATIENT S GUIDE TO SECONDARY PREVENTION IN ACUTE CORONARY SYNDROME (ACS) This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get

More information

East Kent Prescribing Group

East Kent Prescribing Group East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal

More information

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example Ulf Stenestrand, MD, PhD Department of Cardiology University Hospital Linköping Chairman RIKS-HIA Register

More information

POAC CLINICAL GUIDELINE

POAC CLINICAL GUIDELINE POAC CLINICAL GUIDELINE Acute Pylonephritis DIAGNOSIS COMPLICATED PYELONEPHRITIS EXCLUSION CRITERIA: Male Known or suspected renal impairment (egfr < 60) Abnormality of renal tract Known or suspected renal

More information

Disclosures. The FAST-MI registry is a registry of the French Society of Cardiology, supported by unrestricted grants from:

Disclosures. The FAST-MI registry is a registry of the French Society of Cardiology, supported by unrestricted grants from: Impact on early complications of non-compliance with guidelines-recommended timelines for reperfusion therapy in STEMI patients. The FAST-MI 2010 registry E. Puymirat 1, L. Lorgis 2, P. Coste 3, S. Charpentier

More information

Mission: Lifeline Recommendations for Criteria for STEMI Systems of Care

Mission: Lifeline Recommendations for Criteria for STEMI Systems of Care Mission: Lifeline Recommendations for Criteria for STEMI Systems of Care The Mission: Lifeline Certification Program will acknowledge STEMI Systems, EMS, Non-PCI/STEMI Referral Centers and PCI/STEMI Receiving

More information

Community health care services Alternatives to acute admission & Facilitated discharge options. Directory

Community health care services Alternatives to acute admission & Facilitated discharge options. Directory Community health care services Alternatives to acute admission & Facilitated discharge options Directory Introduction The purpose of this directory is to provide primary and secondary health and social

More information

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,

More information

CARDIAC RISKS OF NON CARDIAC SURGERY

CARDIAC RISKS OF NON CARDIAC SURGERY CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management

More information

HOW TO CITE THIS ARTICLE:

HOW TO CITE THIS ARTICLE: CORRELATION OF TIMI RISK SCORE WITH ANGIOGRAPHIC SEVERITY IN PREDICING THE EXTENT OF CORONARY ARTERY DISEASE IN PATIENTS WITH NON ST ELEVATION ACUTE CORONARY SYNDROME N. Senthil 1, S. R. Ramakrishnan 2,

More information

PRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ANTICOAGULANT THERAPY

PRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ANTICOAGULANT THERAPY PRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ON ANTICOAGULANT THERAPY Prepared by: NPSA Anticoagulation Steering Group Approved by: Wirral Drug & Therapeutics Committee 14 th May 2008 Review:

More information

GENERAL HEART DISEASE KNOW THE FACTS

GENERAL HEART DISEASE KNOW THE FACTS GENERAL HEART DISEASE KNOW THE FACTS WHAT IS Heart disease is a broad term meaning any disease affecting the heart. It is commonly used to refer to coronary heart disease (CHD), a more specific term to

More information

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

Stent for Life Initiative How can we improve system delay and patients delay in STEMI Stent for Life Initiative How can we improve system delay and patients delay in STEMI Z. Kaifoszova SFL Initiative Europe 2011 Stent for Life Initiative 10 countries participate in the program Declaration

More information

Atrial Fibrillation An update on diagnosis and management

Atrial Fibrillation An update on diagnosis and management Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.

More information

Perioperative Cardiac Evaluation

Perioperative Cardiac Evaluation Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project

More information

New Oral AntiCoagulants (NOAC) in 2015

New Oral AntiCoagulants (NOAC) in 2015 New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research

More information

ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline

ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline David Zhao, MD, FACC, FSCAI Professor of Medicine and Cardiac Surgery Harry and Shelley Page Professor in Interventional Cardiology

More information

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,

More information

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Issued: March 2015 guidance.nice.org.uk/ta335 NICE has accredited the process used by the Centre for Health

More information

Endoscopy & ACS. 8/1/2014 Dr. Whang

Endoscopy & ACS. 8/1/2014 Dr. Whang Endoscopy & ACS 8/1/2014 Dr. Whang Outline I. Antiplatelets II. Coronary Artery Disease in U.S. III. GI Bleeding in ACS IV. ACC/AHA guidelines: Dual Antiplatelet Therapy in CAD V. PPI and Plavix Controversy

More information

Consultation Draft: Clinical Care Standard for Acute Coronary Syndrome December 2013

Consultation Draft: Clinical Care Standard for Acute Coronary Syndrome December 2013 TRIM: 90512 Consultation Draft: Clinical Care Standard for Acute Coronary Syndrome December 2013 Commonwealth of Australia 2013 This work is copyright. It may be reproduced in whole or in part for study

More information

ACLS PRE-TEST ANNOTATED ANSWER KEY

ACLS PRE-TEST ANNOTATED ANSWER KEY ACLS PRE-TEST ANNOTATED ANSWER KEY June, 2011 Question 1: Question 2: There is no pulse with this rhythm. Question 3: Question 4: Question 5: Question 6: Question 7: Question 8: Question 9: Question 10:

More information

KIH Cardiac Rehabilitation Program

KIH Cardiac Rehabilitation Program KIH Cardiac Rehabilitation Program For any further information Contact: +92-51-2870361-3, 2271154 Feedback@kih.com.pk What is Cardiac Rehabilitation Cardiac rehabilitation describes all measures used to

More information

2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2. Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order

More information

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical

More information

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015 Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?

More information

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

ABOUT XARELTO CLINICAL STUDIES

ABOUT XARELTO CLINICAL STUDIES ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the

More information

Nurse Practitioner. CLINICAL PROTOCOL Chest Pain

Nurse Practitioner. CLINICAL PROTOCOL Chest Pain Nurse INTRODUCTION: Patients presenting with chest pain require rapid evaluation. Myocardial ischaemia should be considered in all patients presenting with chest pain. Assessment of pain type and referral,

More information

Post-MI Cardiac Rehabilitation. Mark Mason Consultant Cardiologist Harefield Hospital Royal Brompton and Harefield NHS Foundation Trust

Post-MI Cardiac Rehabilitation. Mark Mason Consultant Cardiologist Harefield Hospital Royal Brompton and Harefield NHS Foundation Trust Post-MI Cardiac Rehabilitation Mark Mason Consultant Cardiologist Harefield Hospital Royal Brompton and Harefield NHS Foundation Trust 'the sum of activities required to influence favourably the underlying

More information

S9 Administer thrombolytic treatment in acute ischaemic stroke

S9 Administer thrombolytic treatment in acute ischaemic stroke S9 Administer thrombolytic treatment in acute ischaemic Screening and initiating treatment, overseeing competency of treatment About this workforce competence This competence is about the emergency administration

More information

URN: Family name: Given name(s): Address:

URN: Family name: Given name(s): Address: The State of Queensland (Queensland Health) 2012 Contact CIM@health.qld.gov.au Facility: Clinical Pathways Never Replace Clinical Judgement Care Outlined In This Pathway Must be Altered If It Is Not Clinically

More information

Investor science conference call: American College of Cardiology 2015

Investor science conference call: American College of Cardiology 2015 Investor science conference call: American College of Cardiology 2015 San Diego, California, USA 16 March 2015 Cautionary statement regarding forward-looking statements In order, among other things, to

More information

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate

More information

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know Acute Coronary Syndrome What Every Healthcare Professional Needs To Know Background of ACS Acute Coronary Syndrome (ACS) is an umbrella term used to cover a spectrum of clinical conditions that are caused

More information

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant

More information

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015 The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Highlights from Prescribing Information - the link to the full text PI is as follows: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf

More information

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.

More information

Quiz 5 Heart Failure scores (n=163)

Quiz 5 Heart Failure scores (n=163) Quiz 5 Heart Failure summary statistics The correct answers to questions are indicated by *. Students were awarded 2 points for question #3 for either selecting spironolactone or eplerenone. However, the

More information

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012 The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received

More information

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart

More information

National Medicines Information Centre

National Medicines Information Centre National Medicines Information Centre VOLUME 11 NUMBER 4 2005 ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 www.nmic.ie For personal use only. Not to be reproduced without

More information

Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC

Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC NAAMA 37 th National Medical Convention September 5 th, 2015 Atherosclerosis Coronary Heart

More information

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181

More information

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7

More information

Atrial Fibrillation Management Across the Spectrum of Illness

Atrial Fibrillation Management Across the Spectrum of Illness Disclosures Atrial Fibrillation Management Across the Spectrum of Illness NONE Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University Objectives AF Discuss the pathophysiology, diagnosis,

More information

rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc.

rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc. rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc. 05 June 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

More information

The author has no disclosures

The author has no disclosures Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author

More information

Il punto sulla terapia antitrombotica nelle sindromi coronariche acute

Il punto sulla terapia antitrombotica nelle sindromi coronariche acute Santa Margherita Ligure TIGULLIO CARDIOLOGIA 2012 16-17 Febbrajo 2012 Il trattamento dell infarto miocardico acuto ad ST spraslivellato: dal territorio al laboratorio di emodinamica Il punto sulla terapia

More information

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess

More information

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with

More information

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding

More information

Guidelines For Management of Acute Coronary Syndromes

Guidelines For Management of Acute Coronary Syndromes Guidelines For Management of Acute Coronary Syndromes University of California San Francisco Division of Cardiology Department of Clinical Pharmacy (REVISED May 13, 2003) A. Acute Reperfusion Therapy:

More information

CLINICAL GUIDELINE FOR THE MANAGEMENT OF HYPERGLYCAEMIA IN ADULTS WITH ACUTE CORONARY SYNDROME

CLINICAL GUIDELINE FOR THE MANAGEMENT OF HYPERGLYCAEMIA IN ADULTS WITH ACUTE CORONARY SYNDROME CLINICAL GUIDELINE FOR THE MANAGEMENT OF HYPERGLYCAEMIA IN ADULTS WITH ACUTE CORONARY SYNDROME 1. Aim/Purpose of this Guideline This guideline is for the management of Adult patients with Diabetes Mellitus

More information

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological

More information

ACTION Registry GWTG Version 2.4

ACTION Registry GWTG Version 2.4 ACTION Registry GWTG Version 2.4 Dr. Joanne Foody Kim Hustler The following relationships exist: Dr. Foody:Janssen, Sanofi, Genzyme, Aegerion, Amarin, BristolMeyersSquibb, Abbott, Gilead, ACC, Pfizer,

More information

Guideline for Anticoagulation and Prophylaxis Using Low Molecular Weight Heparin (LMWH) in Adult Inpatients

Guideline for Anticoagulation and Prophylaxis Using Low Molecular Weight Heparin (LMWH) in Adult Inpatients Guideline [Optional heading here. Change font size to suit] Document Number # QH-GDL-951:2015 Guideline for Anticoagulation and Prophylaxis Using Low Molecular Weight Heparin (LMWH) in Adult Inpatients

More information

SOUTH EAST WALES CARDIAC NETWORK INTEGRATED CARE PATHWAY CARDIAC REHABILITATION MAY 2005

SOUTH EAST WALES CARDIAC NETWORK INTEGRATED CARE PATHWAY CARDIAC REHABILITATION MAY 2005 Name Address SOUTH EAST WALES CARDIAC NETWORK INTEGRATED CARE PATHWAY CARDIAC REHABILITATION MAY 2005 Ms / Miss / Mr / Mrs Addressograph Known as Telephone Number of Birth Hospital No. NHS No. Cardiac

More information

MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE. Peter Wenaweser Universitätsklinik für Kardiologie

MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE. Peter Wenaweser Universitätsklinik für Kardiologie MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE Peter Wenaweser Universitätsklinik für Kardiologie Scientific Advances & Cardiovascular Mortality 1950 to 2010 Nabel EM and Braunwald

More information

Risk stratification for patients who present to the

Risk stratification for patients who present to the CLINICAL INVESTIGATIONS Application of the TIMI Risk Score for Unstable Angina and Non-ST Elevation Acute Coronary Syndrome to an Unselected Emergency Department Chest Pain Population Charles V. Pollack

More information